t lymphocyte attenuator btla elisa kit  (Cusabio)

Journal: Scientific Reports

Article Title: Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma

doi: 10.1038/s41598-020-60440-5

Figure Lengend Snippet: sBTLA levels predicts outcome of patients with HCC. ( a ) Kaplan-Meier survival analysis of 53 patients with advanced HCC at baseline including high levels of sBTLA and low levels of sBTLA. ( b ) Immunohistochemical staining of BTLA in liver tissues of four patients with HCC. Case 1 was a 21-year-old woman with HBV-related, huge but solitary HCC. Sorafenib was started 17 months after surgery, due to multiple intrahepatic recurrences and lung metastases. The plasma level of sBTLA was 807 pg/mL at the start of sorafenib treatment. Case 2 was a 73-year-old man with HCV-related, solitary HCC with a diameter of 45 mm. Sorafenib was started 12 months after surgery because of multiple intrahepatic recurrences and bone metastases. The plasma sBTLA level was 1,099 pg/mL prior to treatment. Case 3 was a 64-year-old man with alcoholic cirrhosis and solitary HCC at a diameter of 40 mm. Sorafenib was started 6 months after the operation, because of multiple intrahepatic recurrences and hilar lymph node metastasis. Plasma sBTLA levels were 311.08 pg/mL at the time of surgery and 98.9 pg/mL prior to treatment. Case 4 was a 77-year-old woman with HCV-related and solitary HCC with a diameter of 50 mm. Sorafenib treatment was initiated 5 months after surgery because of bone metastasis. PT: peri-tumoral, T: tumor. Scale bar, 50 μm. ( c ) Double immunofluorescent staining of BTLA (green) with CK18 (red), (d) CD68 (red), CD3 (red) or CD20 (red) in HCC tissues obtained from Case 3. Scale bar, 50 μm.

Article Snippet: Intra- and peri-tumoral sections were assessed by IHC and IF, as previously described , using the following primary antibodies and dilution ratios: anti-BTLA (Abcam, rabbit polyclonal anti-CD272 antibody, ab181406, IHC 1:500, IF 1:60), anti-CK18 (Novous, NB500–353, 1:100), anti-CD3 (Dako, Clone F7.2.38, 1:50), anti-CD20 (Dako, Clone L26, 1:200) and anti-CD68 (Dako, clone PG-M1, 1:80).

Techniques: Immunohistochemical staining, Staining

Journal: Molecular Medicine

Article Title: Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness

doi: 10.1186/s10020-018-0036-3

Figure Lengend Snippet: – Soluble BTLA in Critical Illness: SBTLA is increased in the serum of mice (Figure a , p = 0.0037) and humans (Figure b , p < 0.001), but no differences were seen in the BAL fluid of mice ( p = 0.476, Figure c ), and changes in critically ill patient levels of sBTLA on day 0 of hospital admission predict the diagnosis of sepsis (Figure d )

Article Snippet: In mice the soluble level of BTLA was measured in the serum using the BTLA ELISA kit (Cusabio, College Park, MD).

Techniques: Biomarker Discovery

Journal: Molecular Medicine

Article Title: Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness

doi: 10.1186/s10020-018-0036-3

Figure Lengend Snippet: – Frequency of Skipped Exon in BTLA in critically ill mouse model: The skipping of exon 3 is significantly different between critically ill mice (19%, n = 3) and healthy sham controls (0%, n = 3) (FDR =0.0000471413836931, bar graph to the left). The full length isoform is seen 81% of the time in the control mice and 100% of the time in the critically ill mice (bar graph to the right)

Article Snippet: In mice the soluble level of BTLA was measured in the serum using the BTLA ELISA kit (Cusabio, College Park, MD).

Techniques: Control

Journal: Molecular Medicine

Article Title: Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness

doi: 10.1186/s10020-018-0036-3

Figure Lengend Snippet: – Alternative 3’ Splice Site of BTLA: The percentage of an alternative 3′ splice site at exon 4 is significantly different between critically ill mice (40%, n = 3) and healthy controls (53%, n = 3) (FDR =0.0000429857901449, bar graph to the left). The full length isoform is seen 60% of the time in the control mice and 47% of the time in the critically ill mice (bar graph to the right)

Article Snippet: In mice the soluble level of BTLA was measured in the serum using the BTLA ELISA kit (Cusabio, College Park, MD).

Techniques: Control

Journal: Molecular Medicine

Article Title: Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness

doi: 10.1186/s10020-018-0036-3

Figure Lengend Snippet: – Ex Vivo Experiments with BTLA Fusion Protein: When cells came from mice with critical illness there were increased levels of IL-6 ( p = 0.41, Figure a ), IL-9 ( p = 0.019, Figure b ), IL-27 ( p = 0.044, Figure c ) and cellular proliferation ( p = 0.004, Figure d ). The addition of 1000 ng/mL of BTLA fusion protein also increased cellular proliferation ( p = 0.021, Figure d )

Article Snippet: In mice the soluble level of BTLA was measured in the serum using the BTLA ELISA kit (Cusabio, College Park, MD).

Techniques: Ex Vivo